The Latest Breaking News from BioNTech

Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process, 

Macy's Inc (NYSE: M) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors.

Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill

Pfizer and BioNTech said Tuesday they are seeking emergency authorization from US health regulators for use of their Covid vaccine for children aged over six months and under five years. If the Food and Drug Administration (FDA) authorizes the two-shot regimen, it will become the first Covid vaccine available to…

Pfizer-BioNTech seeks US approval for under-5s Covid inoculation; Lithuania to scrap Covid pass on Saturday

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are likely to submit a request for an emergency use authorization to the U.S.

The ongoing market correction has caused the shares of popular vaccine makers Moderna (MRNA) and BioNTech (BNTX) to decline nearly 40% in price so far this year. However, because the demand for COVID-19 vaccines remains strong globally, these companies are expected to generate substantial revenues and profits in the coming…

Someone with a lot of money to spend has taken a bearish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A COVID-19 vaccine specifically targeting the Omicron variant would be "prudent", even if it ultimately may not be needed, the top US infectious disease official says, as Pfizer announces trials for such a vaccine.